Structure Therapeutics

NMQ:GPCR · US86366E1064

PharmaceuticalsSmall

360° View

Value40

Price/Sales4

Price/Earnings86

Price/Book62

Dividend Yield1

Growth63

Revenue Growth—

Profit Growth6

Capital Growth81

TSR 52w80

Safety80

Leverage88

Liquidity9

Refinancing88

Combined63

Sentiment53

Analyst Opinions51

Pro Holdings75

Opinion Changes23

Market Pulse61

Profile

CountryUSA

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2016

Employees183

Websitestructuretx.com

ISINUS86366E1064

Last UpdateApr 2, 2026

Index & Theme

Chronic DiseasesObesityDiabetesCardiovascularRespiratoryBiotechnologyHealth CareMedicalPharmaceuticalProduct Research

Description

Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company, develops novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's differentiated technology platform leverages both structure…

Analysis

Structure Therapeutics's 360° View rank of 67 places it above its peer average — better than 67% of its true peers.

It's growing solidly (63) and on the expensive side (40). On safety it is very well financed (80), and the market shows favorable sentiment (53). Taken together, its Combined rank of 63 reads as above its peer average.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Structure Therapeutics with its peers

AnaptysBio

NSQ:ANAB

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Omeros

NMQ:OMER

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Terns Pharmaceuticals

NSQ:TERN

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

MBX Biosciences

NSQ:MBX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Rapport Therapeutics

NMQ:RAPP

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Ventyx Biosciences

NSQ:VTYX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →